ORIGINAL ARTICLESSerum metabolomics reveals the progression of coronary artery stenosis in patients with hypercholesterolemia a pilot studyQiu, Qia; Wang, Yonge; Jing, Shana; Chen, Yanhuab; Cao, Jinglina; Pan, Yuc; Ye, Mingd; Lin, YangaAuthor Information aDepartment of Pharmacy, Beijing Anzhen Hospital, Capital Medical University bState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College cDepartment of Cardiology dDepartment of Emergency, Beijing Anzhen Hospital, Capital Medical University eDepartment of Biochemistry, Lifescience School, Beijing University of Chinese Medicine, Beijing, People's Republic of China Correspondence to Yang Lin, Department of Pharmacy, Beijing Anzhen Hospital, Capital Medical University, No. 2 Anzhen Road, 100029 Beijing, People's Republic of China Tel: +86 010 64412431; e-mail: [email protected] Received 21 September, 2018 Revised 3 May, 2019 Accepted 13 May, 2019 Blood Coagulation & Fibrinolysis: July 2019 - Volume 30 - Issue 5 - p 205-216 doi: 10.1097/MBC.0000000000000819 Buy Metrics Abstract The current study explores potential characteristic metabolic signatures associated with the high cholesterol (CHO), and the progression of coronary artery stenosis (CAS) in high-CHO patients. A metabolomics strategy based on ultra high-performance liquid chromatography/MS-MS and multivariate statistics has been implemented to identify potential biomarkers in high-CHO patients with different levels of CAS. The current study included 57 individuals, comprising 17 healthy paticipants, and 40 high-CHO patients. The high CHO patients were subgrouped based on the computed tomography angiography results, that is, CHO+ no ART (n = 10), CHO+ ART less than 50% (n = 13), CHO+ ART 50–75% (n = 11), and CHO+ ART more than 75% (n = 6). After metabolomics study, 16 discriminating metabolites in positive ion mode and 17 discriminating metabolites in negative ion mode were regarded as possible biomarker candidates to reflect metabolic traits differences between patients with healthy subjects and CHO. A total of six metabolites were tentatively identified as potential biomarkers for the progression diagnosis of CAS: three lysophosphatidylcholines (Lyso-phosphocholine, lysoPC and Lysopersicon esculentum, lysoPE), proline betaine and tryptophan, and prasterone sulfate. The results demonstrated that tryptophan and proline betaine could differentiate the patients with or without high CHO. Tryptophan, prasterone sulfate, LysoPE (0 : 0/18 : 2) or LysoPE (18 : 2/0 : 0), and LysoPE (0 : 0/18 : 1) or LysoPE (18 : 1/0 : 0) could differentiate the patients with severe stenosis (ART > 70%) from the healthy or mild stenosis ones. Proline betaine and significant decrease of LysoPC (17 : 0) could also be a promising biomarker for the mild stenosis (ART < 50%). Copyright © 2019 YEAR Wolters Kluwer Health, Inc. All rights reserved.